Managing hypertension in diabetic patients - Focus on trandolapril/verapamil combination

Vascular Health and Risk Management

Volumn 3, Issue 4, 2007, Pages 453-465

  Sharma, Sanjib Kumar ^a,c   Ruggenenti, Piero ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Azienda Ospedaliera   (Italy)

^c BP Koirala Institute of Health Sciences ^*  (Nepal)

Author keywords

Diabetes mellitus; Hypertension; Trandolapril; Verapamil SR

Indexed keywords

ALCOHOL; ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR; ANTACID AGENT; ATENOLOL; ATENOLOL PLUS CHLORTALIDONE; ATENOLOL PLUS HYDROCLOROTHIAZIDE; CARBAMAZEPINE; CIMETIDINE; CYCLOSPORIN; DANTROLENE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; ERYTHROMYCIN; FUROSEMIDE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; LITHIUM; PHENOBARBITAL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; QUINIDINE; RIFAMPICIN; RITONAVIR; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FOOD DRUG INTERACTION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; GRAPEFRUIT JUICE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY DISEASE; MALIGNANT HYPERTHERMIA; MAXIMUM PLASMA CONCENTRATION; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INDOLES; TREATMENT OUTCOME; VERAPAMIL;

EID: 35148889836     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Abbott Laboratories. 2002a. Isoptin SR (verapamil HCL) US prescribing information. North Chicago (IL) Abbott Laboratories.
2. Abbott Laboratories. 2002b. Tarka 180/2 mg capsules: summery of product characteristics 2002 [online]. Accessed 2006 Jun 22. URL: http//emc.medicine.org.uk.
3. Abbott Laboratories, North Chicago (IL), USA. 2003a. TARKA® (trandolapril/verapamil hydrochloride ER tablets): prescribing information 2003 [online]. Accessed 2006 Jun 22. URL: http//www.abbott.com/corporate/product_list.cfm.
4. Abbott Laboratories, North Chicago (IL), USA. 2003b. Mavik® (trandolapril tablets): prescribing information 2003 [online]. Accessed 2006 Jun 22. URL: http//www.rxabbott.com/pdf/mavik.pdf.
5. Abuissa H, Bell DSH, O'Keefe Jr JH. 2005. Strategies to prevent type 2 diabetes. Curr Med Res Opin, 21:1107-14.
6. Alder AI, Stevens RJ, Manley SE, et al. 2003. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int, 63:225-32.
7. Alderman MH. 2003. The return on INVEST. JAMA, 290:2859-61.
8. American Diabetes Association. 2004. Hypertension management in adults with diabetes. Diabetes Care, 27:s65-7.
9. Arner P, Wade A, Engfeldt P, et al. 1994. Pharmacokinetics and Pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol, 23(Suppl 4):s44-9.
10. Bakris GL, Burnhill BW, Sadler R, et al. 1992. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int, 41:912-19.
11. Bakris GL, Gaxiola E, Messerli FH, et al. 2004. Clinical outcome in the diabetes cohort on International Verapamil SR-Trandolapril study. Hypertension, 44:637-42.
12. Bakris GL, Weir MR, DeQuattro V, et al. 1998. Effects of an ACE inhibitor/calcium antagonist combination on protenuria in diabetic nephropathy. Kidney Int, 54:1283-9.
13. Bakris GL, Weir MR, Shanifar S, et al. 2003. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med, 163:1555-65.
14. Beckman JA, Creager MA, Libby P. 2002. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA, 287:2570-81.
15. Berl T, Hunsicker LG, Lewis JB, et al for the Collaborative Study Group. 2003. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med, 138:542-9.
16. Berne C, Pollare T, Lithell H. 1991. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE-inhibitors. Diabetes Care, 14(Suppl 4):39-47.
17. Bevan EG, McInnes GT, Aldigier JC, et al. 1993. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril. Br J Clin Pharmacol, 35:128-35.
18. Brenner BM, Cooper ME, de Zeeuw D, et al. 2001. RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345:861-9.
19. Breithaupt-Grogler K, Gerhardt G, Lehmann G, et al. 1998. Blood pressure and aortic elastic properties: verapamil SR/trandolapril compared to metoprolol/hydrochlorthiazide combination thearapy. Int J Clin Pharmacol Ther, 36:425-31.
20. Chobanian AV, Bakris GL, Black HR, et al. 2003. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-125.
21. Choi KL, Bakris GL. 2005. Hypertension treatment Guidelines: practical implications. Semin Nephrol, 25:198-209.
22. Curb JD, Pressel SL, Cutler JA, et al. 1996. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetes patients with isolated systolic hypertension. Systolic Hyperetension in the Elderly Program Cooperative Research Group. JAMA, 276:1886-92.
23. Danielson B, Querin S, LaRochelle P, et al. 1994. Pharmacokinetic and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol, 23(Suppl 4):s50-9.
24. de leeuw PW, Notter T, Zilles P. 1997. Comparison of different fixed antihypertensive combination drugs: a double blind, placebo-controlled, parallel group study. J Hypertens, 15:87-91.
25. DeQuattro V, Lee D, and Trandolapril Study Group. 1997. Fixed dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Am J Hypertens, 10:138s-45s.
26. Dillon JJ. 1993. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am J Kidney Dis, 22:798-802.
27. Dinneen SF, Gerstein HC. 1997. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med, 157:1413-18.
28. Fernández R, Puig JG, Rodríguez-Pérez JC, et al. 2001. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens, 15:849-56.
29. Flack JM, Sowers JR. 1991. Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med, 91:11S-21S.
30. Gall MA, Hougaard P, Borch-Johnsen K, et al. 1997. Risk factors for development of incipient and overt diabetic nephropathyin patients with non insulin dependant diabetes mellitus: prospective observational study. BMJ, 314:783-88.
31. Haansoon L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT study group. Lancet, 351:1755-62.
32. Haegert AM, Swales JD. 1987. The combination of verapamil and captopril in the treatment of essential hypertension. Pharmacotherapeutica, 5(1).
33. Hansen JF, Hangerup L, Sigurd B, et al. 1997. Cardiac events rate after myocaridal infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol, 15:738-41.
34. Harris MI, Flegal KM, Cowie CC, et al. 1998. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care, 21:518-24.
35. Holzgreve H, Nakov R, Beck K, Janka HU. 2003. Antihypertensive therapy with verapamil sr plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens, 16:381-6.
36. Hypertension in Diabetes Study (HDS). 1993. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association of risk factors for cardiovascular and diabetic complicatins. J Hypertens, 11:309-17.
37. Kalberge BE, Andrup M, Oden A, on behalf of the Swidish Tarka Trialists. 2000. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Blood Press, 9:140-5.
38. Lenfant B, Mauren M, Bryce T, et al. 1994. Trandolapril: Pharmacokinetics of single oral dose in healthy male volunteers. J Cardiovasc Pharmacol, 23 (Suppl 4):s238-43.
39. Mancia G, Cooper-DeHoff RM, Hewkin A, et al. 2004. Association of BP control and frequency of mortality and morbidity in hypertensive patients with CAD - The International Verapamil SR-Trandolapril Study [abstract no. p-229]. Am J Hypertens, 15:116a.
40. Mogensen CE. 1976. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest, 36:383-8.
41. Mogensen CE. 1984. Microalbuminuria predicts clinical proteiuria and early mortality in maturity-onset diabetes. N Engl J Med, 310:356-60.
42. Muijsers RBR, Curan MP, Erry CM. 2002. Fixed combination trandolapril/ verapamil sustained-release: a review of its use in essential hypertension. Drugs, 62:2539-67.
43. National Kidney Foundation. 2002. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis, 39 (Suppl 1):S1-266.
44. Nelson RG,. Knowler WC, Pettitt DJ, et al. 1991. Assessing risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimen. Arch Inttrn Med, 151:1761-5.
45. Papine MD, Handberg EM, Cooper-DeHoff RM, et al. 2003. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil SR-Trandolapril Study: a randomized controlled trial. JAMA, 290:2805-16.
46. Parving HH, Lehnert H, Brochner-Mortensen J, et al. 2001. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 345:870-78.
47. Perneger TV, Brancati F, Whelton PK, et al. End-stage renal disease attributable to diabetes mellitus. 1994. Ann Intern Med, 121:912-18.
48. Pohl MA, Blumenthal S, Cordonnier DJ, et al. 2005. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol, 16:3027-37.
49. Raynolds NA, Wagstaff AJ, Keam SJ. 2005. Trandolapril/verapamil sustained released: a review of its use in the treatment of Eessential hypertension. Drugs, 65:1893-1914.
50. Reid LD, Tueth MJ, Handberg E, et al. 2005. A study of antihypertensive drug and depressive symptoms (SADD-Sx) in patients treated with calcium antagonist versus an atenolol hyepretension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosom Med, 67:398-406.
51. Remuzzi G, Macia M, Ruggenenti P. 2006. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol, 17:S90-7.
52. Romos F, Baglovo H, Sanchez R. 2001. Comparative double blind study at fixed dose of trandolapril+verapamil vs. atenolol+chorthalidon in mild to moderate hypertensive patients [abstract no. p3.185]. J Hypertens, 19 (Supp 12):s236.
53. Ruggenenti P, Fassi A, Ilieva AP, et al: for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. 2004. Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 351:1941-51.
54. Ruggenenti P, Perna A, Ganeva M, et al. 2006. Impact of blood pressure control and ace inhibitor therapy on newly onset microalbuminuria in type 2 diabetes: a post-hoc analysis of the BENEDICT trial. J AM Soc Nephrol, 17:3472-81.
55. Ruggenenti P, Remuzzi G. 2006. Time to abandon microalbuminuria? Kidney Int, 70:1214-22.
56. Ruilope LM. 2002. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomised double-blind trial. J Hypertens, 20:729-37.
57. Ruilope LM, Usan L, Segura J, et al. 2004. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens, 22:217-22.
58. Schneider M, Lerch M, Papiri M, et al. 1996. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlorthalodone treatment in hypertesnsive type 2 diabetes. J Hypertens, 14:669-77.
59. Sica DA. 2002. Rationale for fixed-dose combination in the treatment of hypertension: the cycle repeats. Drugs, 62:443-452.
60. Siepman M, Rao BR, Kirch W. 1997. Disposition, elimination and haemodynamic effects of varapamil and trandolapril in patients with fatty liver disease. Clin Drug Invest, 14:376-82.
61. Sowers JR. 1995. Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Nephrol Dial Transplant, 10 (Suppl 9):52-5.
62. Sowers J, Bakris GL. 2000. Antihypertensive therapy and risk of type 2 diabetes mellitus. N Engl J Med, 342:969-70.
63. Strippoli GFM, Craig M, Schena FP, et al. 2005. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol, 16:3081-91.
64. Sutter PM, Vettr W. 1995. Metabolic effects of antihypertensive drugs. J Hypertens, 13 (Suppl 4):s11-s17.
65. Sweetman S (ed). 2005. Martindale: the complete drug reference. London. Pharmaceutical press. Electronic version. Dantrolin sodium [online]. Accessed 2005 December 2. URL: http://www.medicinecomplete.com/mc/ martindales.
66. Tatti P, Pahor M, Byington RP, et al. 1998. Outcome results of fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 21:597-603.
67. The BENEDICT Group. 2003. The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT): Design and baselines group. Control Clin Trials, 24:442-61.
68. The Heart Outcome Prevention Evaluation Study Investigators. 2000. Effects of an angiotensine-converting-anzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 342:145-53.
69. The Veratran study group. 1997. The effects of verapamil SR, trandolapril and their fix combination on 24-h blood pressure: the Veratran Study. Am J Hypertens, 10:492-9.
70. Topouchian J, Asmar R, Sayegh F, et al. 1999. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke, 30:1056-64.
71. UK Prospective Diabetes Study Group. 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. BMJ, 317:703-13.
72. Viskoper RJ, Compagnone D, Dies R, et al. 1997. Verapamil and trandolapril alone and fixed combination on 24-hour ambulatory blood pressure profile of patients with moderate essential hypertesnsion. Curr Ther Res Clin Exp, 58:343-51.
73. Waeber B. 2003. Trails in isolated systolic hypertension: an update. Curr Hypertension Rep, 5:329-36.
74. Widimsky J. 2000. The fixed combination of verapamil SR/trandolapril. Expert Opin Pharmacother, 1:515-35.
75. Wiserman LR, McTavish D. 1994. Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs, 48 (1):71-90.
76. Wild S, Roglic G, Green A, et al. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 27:1047-53.
77. World Health Report. 2003. Sharing the Future. Neglected Global Epidemics: three growing threats in Report of World Health Organization, Geneva 2003.